GlassScriptPhysician profile
Chelsea Geiger
NPI 1265120034
$1,964.16
in general payments reported to CMS, 2019-2025
27 companies · $1,621 in 2025
The $1,621 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $343 · 2025: $1,621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,964.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $541.59 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $247.61 | 2024-2025 | Caplyta |
| Lilly USA, LLC | $177.93 | 2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $139.31 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $135.72 | 2025 | |
| Axsome Therapeutics, INC. | $106.96 | 2025 | Auvelity, Sunosi |
| Astrazeneca Pharmaceuticals LP | $83.88 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $82.78 | 2024-2025 | Repatha, Otezla, Otezla |
| Madrigal Pharmaceuticals | $53.24 | 2025 | Rezdiffra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.54 | 2025 | Ofev |
| Vanda Pharmaceuticals INC. | $36.64 | 2025 | Fanapt |
| Ardelyx, INC. | $32.15 | 2025 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $27.98 | 2025 | Eliquis |
| Rgh Enterprises LLC | $24.00 | 2025 | |
| Aimmune Therapeutics, INC. | $23.70 | 2025 | Vowst |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $21.20 | 2025 | Qutenza |
| Exact Sciences Corporation | $19.75 | 2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $19.66 | 2025 | Shingrix |
| Bioventus LLC | $18.82 | 2025 | Durolane |
| Antares Pharma, INC. | $17.95 | 2025 | Xyosted |
| Dexcom, INC. | $17.06 | 2025 | Dexcom G6 Transmitter |
| Abiomed | $16.04 | 2025 | |
| Owp Pharmaceuticals, INC. | $15.66 | 2025 | Subvenite |
| Corcept Therapeutics | $14.78 | 2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $14.74 | 2025 | |
| Phathom Pharmaceuticals, INC. | $14.35 | 2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $14.12 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chelsea Geiger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.